Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

SUMO-specific protease 1 promotes prostate cancer progression and metastasis.

Wang Q, Xia N, Li T, Xu Y, Zou Y, Zuo Y, Fan Q, Bawa-Khalfe T, Yeh ET, Cheng J.

Oncogene. 2013 May 9;32(19):2493-8. doi: 10.1038/onc.2012.250. Epub 2012 Jun 25.

PMID:
22733136
2.

Prognostic impact of SUMO-specific protease 1 (SENP1) in prostate cancer patients undergoing radical prostatectomy.

Li T, Huang S, Dong M, Gui Y, Wu D.

Urol Oncol. 2013 Nov;31(8):1539-45. doi: 10.1016/j.urolonc.2012.03.007. Epub 2012 Oct 22.

PMID:
23089540
3.

SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms.

Bawa-Khalfe T, Cheng J, Lin SH, Ittmann MM, Yeh ET.

J Biol Chem. 2010 Aug 13;285(33):25859-66. doi: 10.1074/jbc.M110.134874. Epub 2010 Jun 15.

4.

Induction of the SUMO-specific protease 1 transcription by the androgen receptor in prostate cancer cells.

Bawa-Khalfe T, Cheng J, Wang Z, Yeh ET.

J Biol Chem. 2007 Dec 28;282(52):37341-9. Epub 2007 Oct 11.

5.

SENP1 protects against myocardial ischaemia/reperfusion injury via a HIF1α-dependent pathway.

Gu J, Fan Y, Liu X, Zhou L, Cheng J, Cai R, Xue S.

Cardiovasc Res. 2014 Oct 1;104(1):83-92. doi: 10.1093/cvr/cvu177. Epub 2014 Jul 31.

PMID:
25082844
6.

Tumor-suppressive microRNA-145 induces growth arrest by targeting SENP1 in human prostate cancer cells.

Wang C, Tao W, Ni S, Chen Q, Zhao Z, Ma L, Fu Y, Jiao Z.

Cancer Sci. 2015 Apr;106(4):375-82. doi: 10.1111/cas.12626. Epub 2015 Mar 16.

7.

SUMO-specific protease 1 regulates the in vitro and in vivo growth of colon cancer cells with the upregulated expression of CDK inhibitors.

Xu Y, Li J, Zuo Y, Deng J, Wang LS, Chen GQ.

Cancer Lett. 2011 Oct 1;309(1):78-84. doi: 10.1016/j.canlet.2011.05.019. Epub 2011 Jun 12.

PMID:
21669491
8.

SUMO-specific protease 1 modulates cadmium-augmented transcriptional activity of androgen receptor (AR) by reversing AR SUMOylation.

Wu R, Cui Y, Yuan X, Yuan H, Wang Y, He J, Zhao J, Peng S.

Toxicol Lett. 2014 Sep 2;229(2):405-13. doi: 10.1016/j.toxlet.2014.07.003. Epub 2014 Jul 8.

PMID:
25014244
9.

Expression and role of Foxa proteins in prostate cancer.

Mirosevich J, Gao N, Gupta A, Shappell SB, Jove R, Matusik RJ.

Prostate. 2006 Jul 1;66(10):1013-28.

PMID:
16001449
10.

Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway.

Ni J, Wen X, Yao J, Chang HC, Yin Y, Zhang M, Xie S, Chen M, Simons B, Chang P, di Sant'Agnese A, Messing EM, Yeh S.

Cancer Res. 2005 Nov 1;65(21):9807-16.

11.

Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance.

Monet M, Lehen'kyi V, Gackiere F, Firlej V, Vandenberghe M, Roudbaraki M, Gkika D, Pourtier A, Bidaux G, Slomianny C, Delcourt P, Rassendren F, Bergerat JP, Ceraline J, Cabon F, Humez S, Prevarskaya N.

Cancer Res. 2010 Feb 1;70(3):1225-35. doi: 10.1158/0008-5472.CAN-09-2205. Epub 2010 Jan 26.

12.

Role of desumoylation in the development of prostate cancer.

Cheng J, Bawa T, Lee P, Gong L, Yeh ET.

Neoplasia. 2006 Aug;8(8):667-76. Review.

13.

SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells.

Kaikkonen S, Jääskeläinen T, Karvonen U, Rytinki MM, Makkonen H, Gioeli D, Paschal BM, Palvimo JJ.

Mol Endocrinol. 2009 Mar;23(3):292-307. doi: 10.1210/me.2008-0219. Epub 2008 Dec 30.

14.

Upregulation of SATB1 is associated with prostate cancer aggressiveness and disease progression.

Shukla S, Sharma H, Abbas A, MacLennan GT, Fu P, Danielpour D, Gupta S.

PLoS One. 2013;8(1):e53527. doi: 10.1371/journal.pone.0053527. Epub 2013 Jan 7.

15.

Loss of receptor protein tyrosine phosphatase β/ζ (RPTPβ/ζ) promotes prostate cancer metastasis.

Diamantopoulou Z, Kitsou P, Menashi S, Courty J, Katsoris P.

J Biol Chem. 2012 Nov 23;287(48):40339-49. doi: 10.1074/jbc.M112.405852. Epub 2012 Oct 11.

16.

LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling.

Lue HW, Yang X, Wang R, Qian W, Xu RZ, Lyles R, Osunkoya AO, Zhou BP, Vessella RL, Zayzafoon M, Liu ZR, Zhau HE, Chung LW.

PLoS One. 2011;6(11):e27720. doi: 10.1371/journal.pone.0027720. Epub 2011 Nov 16.

17.
18.

Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression.

Agoulnik IU, Vaid A, Bingman WE 3rd, Erdeme H, Frolov A, Smith CL, Ayala G, Ittmann MM, Weigel NL.

Cancer Res. 2005 Sep 1;65(17):7959-67.

19.

SENP1 desensitizes hypoxic ovarian cancer cells to cisplatin by up-regulating HIF-1α.

Ao Q, Su W, Guo S, Cai L, Huang L.

Sci Rep. 2015 Nov 9;5:16396. doi: 10.1038/srep16396.

20.

Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome.

Huang M, Narita S, Tsuchiya N, Ma Z, Numakura K, Obara T, Tsuruta H, Saito M, Inoue T, Horikawa Y, Satoh S, Habuchi T.

Carcinogenesis. 2011 Nov;32(11):1589-96. doi: 10.1093/carcin/bgr182. Epub 2011 Aug 8.

PMID:
21828059

Supplemental Content

Support Center